Table 3.
Sex, Age, and Clinical Characteristics of Patients With COVID-19 and Candidemia in the Included Studies
| Author | Age, Mean (SD) or Median [IQR] | Male, % | Antifungal Treatment, % | Antibiotic Treatment, % | Steroid Treatment, % | HTX, % | DM, % | CKD, % | COPD, % | IS, % | NET, % | CVC, % | EOT, % | RRT, % | Surgery, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allaw, 2022 | 68.4 (14.2) | 59.4 | n/a | 100 | 100 | n/a | 40.6 | 18.8 | 21.9 | 18.7 | 3.1 | 93.8 | 84.4 | 25 | n/a |
| Altinkaya Çavus, 2022 | 71.33 (13.67) | 69.2 | 43.5 | 96.1 | 62.8 | 38.4 | 29.4 | 17.9 | 17.9 | 16.6 | 30.8 | 53 | 62.8 | 14.2 | n/a |
| Arastehfar, 2021 | 51.5 (22.3) | n/a | 100 | 100 | n/a | n/a | 16.7 | n/a | n/a | 16.7 | 100 | 100 | 83.3 | n/a | 16.7 |
| Arastehfar, 2022 | 65 [50–73] | 75 | 96 | 100 | 71 | 39 | 21 | 14 | 24 | 32 | n/a | 86 | 89 | n/a | n/a |
| Avkan-Oğuz, 2022 | 69 | 33.3 | 100 | 100 | 100 | n/a | 33.3 | n/a | n/a | 33.3 | n/a | 100 | 100 | n/a | n/a |
| Ayalon, 2022 | n/a | n/a | 81.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Bardi, 2022 | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Beştepe, 2022 | 74.8 (10) | 61 | 52 | 100 | 100 | 61 | 50 | 21 | 25 | 73 | 87 | 80 | 89 | n/a | n/a |
| Bishburg, 2021 | 65 [48–73] | 50 | 100 | 100 | 100 | n/a | n/a | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a |
| Boachie, 2022 | 66 (10) | 61 | 82 | 91 | 96 | 65 | 52 | 22 | 9 | n/a | n/a | 74 | 87 | 39 | n/a |
| Bretagne, 2021 | 65 (18) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ceccarelli, 2022 | n/a | n/a | 100 | 100 | 100 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | no | n/a | n/a |
| Coskun, 2021 | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a |
| Dixit, 2022 | 62 [54.5–72] | 67 | 93.8 | 100 | 74.7 | 63.7 | 41.8 | 8.8 | 13.2 | 6.6 | 9.9 | 94.5 | 69.2 | n/a | n/a |
| Ioannou, 2022 | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Kubin, 2021 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Macauley, 2021 | 62 (16) | 75 | n/a | 100 | 50 | n/a | 8 | 0 | n/a | 0 | 16 | 100 | 92 | 83 | n/a |
| Machado, 2022 | 65.5 [58–73.8] | 71.9 | 93.7 | 96.9 | 84.4 | n/a | 21.9 | 15.6 | 12.5 | 38.4 | 100 | 93.8 | n/a | 18.8 | 9.4 |
| Moin, 2021 | 56.8 [0.8–82] | 61.5 | 88.4 | 100 | 84.6 | n/a | n/a | n/a | n/a | 3.8 | n/a | 73.1 | 80.7 | n/a | n/a |
| Nucci, 2021 | 62 [54–87] | 55.5 | 66.7 | n/a | n/a | n/a | 33.3 | 11.1 | 0 | 11,1 | 0 | 100 | 100 | 0 | 0 |
| Omrani, 2021 | 61 [51–70] | 85 | 88 | n/a | 88.7 | 56.3 | 48.8 | 18.8 | 6.3 | 3.8 | n/a | 96.3 | 95 | 45 | 1.3 |
| Papadimitriou-Olivgeris, 2022 | 68 [58–77] | 62.3 | 40.3 | 100 | 94.8 | n/a | 28.6 | 6.5 | 15.6 | 16.9 | n/a | n/a | n/a | n/a | 7.8 |
| Routsi, 2022 | 69 [15.8] | 72.4 | n/a | n/a | n/a | n/a | 25.8 | n/a | n/a | 8.1 | n/a | n/a | n/a | n/a | n/a |
| Sarvestani, 2021 | 57.5 [32–85] | 33.3 | 100 | 100 | n/a | n/a | 50 | n/a | n/a | 100 | n/a | 100 | 100 | n/a | n/a |
| Seagle, 2022 | n/a | 64.1 | 85.9 | 89.1 | 53.1 | n/a | 53.1 | 7.8 | 28.1 | 15.7 | 6.3 | 79.7 | 81 | 37.5 | 4.7 |
| Silva, 2021 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Age is expressed as mean (SD) or median [IQR], and other variables are expressed as %.
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CVC, central venous catheter; DM, diabetes mellitus; EOT, endo-oral tube; HTX, hypertension; IQR, interquartile range; IS, immunosuppressive status; NET, enteral nutrition therapy; RRT, renal replacement therapy.